Janice M Parker

US Patent:

6610746, Aug 26, 2003

Filed:

Apr 10, 2001

Appl. No.:

09/829874

Inventors:

David A. Fryburg - East Lyme CT
Janice C. Parker - Ledyard CT

Assignee:

Pfizer Inc. - New York NY

International Classification:

A61K 3164

US Classification:

514592, 514 3, 514350, 514352, 514356, 514396

Abstract:

The present invention provides methods of treating non-insulin dependent diabetes mellitus, insulin resistance, Syndrome X, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, polycystic ovary syndrome, cataracts, hyperglycemia, or impaired glucose tolerance, the methods comprising the step of administering to a patient having or at risk of having non-insulin dependent diabetes mellitus, insulin resistance, Syndrome X, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, polycystic ovary syndrome, cataracts, hyperglycemia, or impaired glucose tolerance a synergistic amount of:1) a sulfonylurea, a non-sulfonylurea K ATP channel blocker, or a sulfonylurea and a non-sulfonylurea K ATP channel blocker; and 2) a cAMP phosphodiesterase type 3 inhibitor. The present invention also provides kits and pharmaceutical compositions that comprise: 1) a sulfonylurea, a non-sulfonylurea K ATP channel blocker, or a sulfonylurea and a non-sulfonylurea K ATP channel blocker; and 2) a cAMP phosphodiesterase type 3 inhibitor. The present invention also relates to kits and pharmaceutical compositions that comprise 1) a sulfonylurea, a non-sulfonylurea K ATP channel blocker, or a sulfonylurea and a non-sulfonylurea K ATP channel blocker; 2) a cAMP phosphodiesterase type 3 inhibitor; and 3) an additional compound useful for the treatment of non-insulin dependent diabetes mellitus, insulin resistance, Syndrome X, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, polycystic ovary syndrome, cataracts, hyperglycemia, or impaired glucose tolerance.

US Patent:

6710040, Mar 23, 2004

Filed:

Jun 3, 2003

Appl. No.:

10/455734

Inventors:

Bernard Hulin - Essex CT
Janice C. Parker - Ledyard CT

Assignee:

Pfizer Inc. - New York NY

International Classification:

C07D20504

US Classification:

51421017, 514315, 514330, 514423, 546226, 546245, 548540, 548953

Abstract:

The invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes mellitus, hyperglycemia, impaired glucose tolerance, metabolic syndrome (Syndrome X or insulin resistance syndrome), glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of identifying an insulin secretagogue agent for diabetes.

US Patent:

20030216294, Nov 20, 2003

Filed:

Jun 5, 2003

Appl. No.:

10/456371

Inventors:

David Fryburg - East Lyme CT, US
Janice Parker - Ledyard CT, US

Assignee:

Pfizer Inc.

International Classification:

A61K038/28
A61K031/4439
A61K031/426
A61K031/175

US Classification:

514/003000, 514/365000, 514/342000, 514/592000

Abstract:

The present invention provides methods of treating non-insulin dependent diabetes mellitus, insulin resistance, Syndrome X, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, polycystic ovary syndrome, cataracts, hyperglycemia, or impaired glucose tolerance, the methods comprising the step of administering to a patient having or at risk of having non-insulin dependent diabetes mellitus, insulin resistance, Syndrome X, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, polycystic ovary syndrome, cataracts, hyperglycemia, or impaired glucose tolerance a synergistic amount of: 1) a sulfonylurea, a non-sulfonylurea K ATP channel blocker, or a sulfonylurea and a non-sulfonylurea K ATP channel blocker; and 2) a cAMP phosphodiesterase type 3 inhibitor. The present invention also provides kits and pharmaceutical compositions that comprise: 1) a sulfonylurea, a non-sulfonylurea K ATP channel blocker, or a sulfonylurea and a non-sulfonylurea K ATP channel blocker; and 2) a cAMP phosphodiesterase type 3 inhibitor. The present invention also relates to kits and pharmaceutical compositions that comprise 1) a sulfonylurea, a non-sulfonylurea K ATP channel blocker, or a sulfonylurea and a non-sulfonylurea K ATP channel blocker; 2) a cAMP phosphodiesterase type 3 inhibitor; and 3) an additional compound useful for the treatment of non-insulin dependent diabetes mellitus, insulin resistance, Syndrome X, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, polycystic ovary syndrome, cataracts, hyperglycemia, or impaired glucose tolerance.

US Patent:

20040132713, Jul 8, 2004

Filed:

Dec 19, 2003

Appl. No.:

10/742657

Inventors:

Bernard Hulin - Essex CT, US
Janice Parker - Ledyard CT, US

Assignee:

Pfizer Inc

International Classification:

A61K031/397
A61K031/445
C07D211/60
A61K031/401

US Classification:

514/210170, 514/330000, 548/953000, 546/245000, 514/423000, 548/537000

Abstract:

The invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes mellitus, hyperglycemia, impaired glucose tolerance, metabolic syndrome (Syndrome X or insulin resistance syndrome), glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of identifying an insulin secretagogue agent for diabetes.

US Patent:

20050043292, Feb 24, 2005

Filed:

Aug 19, 2004

Appl. No.:

10/923146

Inventors:

Janice Parker - Ledyard CT, US
Bernard Hulin - Essex CT, US

International Classification:

A61K031/397
A61K031/445

US Classification:

514210170, 514330000, 548953000, 546245000

Abstract:

The invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV (“DPP-IV”), pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes, metabolic syndrome (syndrome X or insulin resistance syndrome), hyperglycemia, impaired glucose tolerance, glucosuria, metabolic acidosis, arthritis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of identifying an insulin secretagogue agent for diabetes.

US Patent:

20050234065, Oct 20, 2005

Filed:

Apr 8, 2005

Appl. No.:

11/102394

Inventors:

Bernard Hulin - Essex CT, US
Janice Parker - Ledyard CT, US
David Piotrowski - Groton CT, US

International Classification:

A61K031/519
A61K031/498
C07D471/02
C07D491/02
C07D498/02

US Classification:

514249000, 514365000, 514423000, 514303000, 514301000, 514265100, 514302000, 514373000, 544330000, 544281000, 546114000, 546115000, 546118000, 548537000, 548200000

Abstract:

The invention provides compounds of Formula (I) or prodrugs thereof, or pharmaceutically acceptable salts of said compounds or prodrugs, or solvates of said compounds, prodrugs or salts, wherein A, N, X and Rare as defined herein; pharmaceutical compositions thereof; and methods of using the pharmaceutical compositions for the treatment of diseases, including Type 2 diabetes, Type 1 diabetes, impaired glucose tolerance, hyperglycemia, metabolic syndrome (syndrome X and/or insulin resistance syndrome), glucosuria, metabolic acidosis, arthritis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, short stature due to growth hormone deficiency, infertility due to polycystic ovary syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome; short bowel syndrome; and the prevention of disease progression in Type 2 diabetes.

Author:

Janice Parker

ISBN #:

0613050878

Author:

Janice Parker

ISBN #:

0613085612

Author:

Janice Parker

ISBN #:

0739801317

Author:

Janice Parker

ISBN #:

0739801333

Author:

Janice Parker

ISBN #:

0739801384

Author:

Janice Parker

ISBN #:

0739801422

Author:

Janice Parker

ISBN #:

0739816829

Author:

Janice Parker

ISBN #:

0817245634